Patient characteristics and ductal lavage cytology results
| Patient characteristics* . | Insufficient cellular material for diagnosis (n = 8) . | Benign cells (n = 35) . | Two-sided P value†,‡ . | Atypical cells (n = 17) . | Two-sided P value†,§ . |
|---|---|---|---|---|---|
| Median age (years) | 44.5 | 42 | 0.072 | 38 | 0.63 |
| Prior breast cancer | 5 (62.5%) | 5 (14.3%) | 0.01 | 4 (23.5%) | 0.45 |
| Prior ovarian cancer | 0 (0%) | 3 (8.6%) | 1.0 | 3 (17.7%) | 0.38 |
| Prior breast or ovarian cancer | 5 (62.5%) | 8 (22.9%) | 0.042 | 7 (41.2%) | 0.20 |
| Prior chemotherapy | 5 (62.5%) | 7 (20.0%) | 0.028 | 7 (41.2%) | 0.18 |
| Prior breast radiation | 3 (37.5%) | 3 (8.6%) | 0.067 | 3 (17.7%) | 0.38 |
| Ever fluid-yielding on suction aspiration | 1 (12.5%) | 19 (54.3%) | 0.05 | 9 (52.9%) | 1.0 |
| Patient characteristics* . | Insufficient cellular material for diagnosis (n = 8) . | Benign cells (n = 35) . | Two-sided P value†,‡ . | Atypical cells (n = 17) . | Two-sided P value†,§ . |
|---|---|---|---|---|---|
| Median age (years) | 44.5 | 42 | 0.072 | 38 | 0.63 |
| Prior breast cancer | 5 (62.5%) | 5 (14.3%) | 0.01 | 4 (23.5%) | 0.45 |
| Prior ovarian cancer | 0 (0%) | 3 (8.6%) | 1.0 | 3 (17.7%) | 0.38 |
| Prior breast or ovarian cancer | 5 (62.5%) | 8 (22.9%) | 0.042 | 7 (41.2%) | 0.20 |
| Prior chemotherapy | 5 (62.5%) | 7 (20.0%) | 0.028 | 7 (41.2%) | 0.18 |
| Prior breast radiation | 3 (37.5%) | 3 (8.6%) | 0.067 | 3 (17.7%) | 0.38 |
| Ever fluid-yielding on suction aspiration | 1 (12.5%) | 19 (54.3%) | 0.05 | 9 (52.9%) | 1.0 |
There were no significant differences between groups in BRCA mutation status, prior or current selective estrogen response modulator, oral contraceptive, and hormone replacement therapy use, parity, prior breast-feeding, menopausal status, bilateral salpingo-oophorectomy before ductal lavage, and prior breast biopsy.
Two-sided P values from Fisher's exact test for categorical variables and Mann-Whitney U test for continuous variables.
For comparison of patients with insufficient cellular material for diagnosis versus patients with benign cells.
For comparison of patients with benign cells versus patients with atypical cells.